Reply  by Kedora, John
LETTERS TO THE EDITOR
Regarding “Randomized comparison of percutaneous
Viabahn stent grafts vs prosthetic femoral-popliteal
bypass in the treatment of superficial femoral arterial
occlusive disease”
Until recently, very few randomized studies have been per-
formed on nonpharmacologic treatment of vascular patients.
Therefore, the study by Kedora et al (J Vasc Surg 2007;45:10-16)
comparing two interventional methods is more than welcome. The
authors are to be congratulated for at least two reasons. One is that
they performed a randomized study of this type, which is difficult,
and the other illustrates the huge gap in study outline compared
with randomized study on pharmacologic therapy. It is also wel-
come because it points to the need for properly designed studies on
nonpharmacologic treatment. I have a few questions and com-
ments for the authors:
1. The population of above knee reconstructions points to a rather
benign problem of below groin disease, and there is no defini-
tion of lifestyle-altering claudication. Is it ethical to use a
synthetic material in this situation?
2. Randomization was made by limb, but the limbs are not inde-
pendent in one patient. Although not many bilateral recon-
structions were done, this principle could skew the results.
3. No information is given on sample size calculation.
4. No information is given on whether the study was designed as
a superiority or noninferiority trial, which also would influence
the sample size.
5. The choice of bypass material was left to the discretion of the
surgeon (polytetrafluoroethylene [PTFE] or polyester). Would
it not have been more optimal to use the same material as in the
stent graft (PTFE)?
6. The use of postoperative antiplatelet therapy was not standard-
ized, meaning that 52% of the patients in the bypass group were
given clopidogrel vs 90% in the stent graft group. This could be
an advantage for the stent graft group.
7. There is no definition of 50% stenosis. How was that measured?
8. We have no information if outcome assessment was made in a
blinded manner.
I believe that answers to the above questions would help
readers in how to interpret the results of the study.
David Bergqvist, MD, PhD, FRCS
Professor of Vascular Surgery
Department of Surgical Sciences, Section of Surgery
Uppsala University Hospital
Uppsala, Sweden
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Reply
The comments by Dr Bergqvist are welcome and offer addi-
tional insight to our study. The study was designed to evaluate all
patients with superficial femoral arterial occlusive disease that were
to be considered for revascularization. All patients with lifestyle-
limiting claudication had failed attempts at conservative treatment
alone. Although the study cohort included patients with claudica-
tion, as Dr Bergqvist states, it also included those patients with rest
pain and tissue loss. These patient-specific data are outlined by
Rutherford’s clinical classification for ischemia in tabular form in
the article.
We certainly do not argue that venous conduit is still consid-
ered the gold standard for vascular reconstruction in the lower
extremities. Our study, however, was not designed to compare
autologous conduit with synthetic material but, rather, to compare
a percutaneous treatment option with open surgical revasculariza-
tion using synthetic material in both treatment arms. Synthetic
material has been studied and used in the reconstruction of super-
ficial femoral arterial disease for a number of years by many
surgeons as evidenced by numerous publications, including a more
recent meta-analysis of 4000 limbs by Dorrucci1 and in a second
report by Bates et al.2 The ethical consideration for any procedure
must be assessed by each physician based on his or her own skill
level and comfort level with the procedure to be considered. Each
patient’s symptoms must also be assessed individually before de-
ciding to proceed with any intervention, and these two treatment
options are certainly no different.
Randomization by limb was performed in all cases, and both
limbs were randomized in 14 patients. There was no statistical
difference in the patient demographic information, as is outlined in
our paper. Because there are no differences in the demographic
stratification and the limbs were prospectively randomized, the
results should not be skewed by the subset of patients with bilateral
randomization.
The study was intended as a noninferiority design, and 50
limbs in each group (100 limbs total) result in a margin of 24% if
we use   0.05 and power  80%. The expanded polytetrafluo-
roethylene (ePTFE)–covered stent graft is considered noninferior
to femoropopliteal surgical bypass if the true patency rate remains
24% of open surgical bypass. This outcome is, in fact, supported
in our study’s primary patency rate of 73% at 1 year for ePTFE
covered stent grafts and 79% at 1 year for surgical femoropopliteal
bypass.
The sample size was calculated before enrollment, allowing for
adequate patient numbers to result in a study powered for a
noninferiority trial. We felt that if we could demonstrate the
outcome between the two treatment arms was equivalent, the
advantage would be gained/realized in the percutaneous arm by a
faster recovery and return to active life with a shorter hospital stay
and less periprocedural pain.
Dacron and ePTFE grafts were allowed for use as a synthetic
conduit at the discretion of the operating surgeon. The goal was to
compare synthetic conduit of the most common types being used
in current everyday practice with the ePTFE-covered stent graft.
We felt that limiting the choice would have only diminished the
value of the study. To our knowledge, no large study has demon-
strated a clear statistically significant difference in the use of ePTFE
vs Dacron for arterial bypass conduit above the knee.
Postoperative clopidogrel was used in 37 (93%) of the 40
patients in the stent graft group. Two patients refused the medi-
cation but did take aspirin, and one patient claimed an allergy to
clopidogrel. In the surgical arm, 24 (52%) of 46 patients were
treated with clopidogrel. Five patients were taking warfarin preop-
eratively, and they were continued on this postoperatively. Seven-
teen patients were treated with aspirin only at the recommendation
of the treating physician. Although this discrepancy could be seen
as an advantage for the stent graft group, there was no statistical
difference between the surgical patients treated with clopidogrel
and those that were not. In addition, our surgical arm patency data
is comparable with historical studies; therefore, we believe there is
no indication of any advantage for either group.1-5 Additional
studies specifically designed to evaluate any advantage the use of
clopidogrel might offer in these two study arms would be helpful
and are being considered at our own institution.
Follow-up was performed by each individual treating physi-
cian; therefore, outcome assessment was not blinded. Follow-up
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arterial duplex was performed on all patients. Failure was defined as
the presence of 50% stenosis within or immediately adjacent to
the surgical bypass or ePTFE-covered stent graft. A stenosis of
50% was defined by B-mode imaging and color flow duplex
scanning that demonstrated arterial velocities of 150 cm/s or a
flow ratio of 2.5.
John Kedora, MD
Department of Surgery
Baylor University Medical Center
Dallas, Tex
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Regarding: “Neovascularization: An ‘innocent
bystander’ in recurrent varicose veins”
In this article, the authors present the preoperative duplex
scanning (DS) and operative findings of a series of 500 consecutive
patients treated by redo surgery between 1995 and 2005 for
recurrent varices after surgery (REVAS) in the great saphenous
vein (GSV) system.1 All patients had previous surgery to the
saphenofemoral junction (SFJ) but the initial surgery was per-
formed over a wide time period in many institutions, presumably
by a variety of surgeons.
DS identified a completely intact GSV system in 17.4%; in-
competent thigh saphenous veins in 44.2% and GSV stump incom-
petence with one or more intact tributaries in 37.6%. Both a
residual thigh GSV and an incompetent stump with intact tribu-
taries were present in 16%. These facts testify to inadequate groin
surgery.
Neovascularization was identified on DS in only 8.2% of limbs
(41/500). However, in 27/41 of these, surgical exploration re-
vealed a residual GSV stump with one or more tributaries. Each of
the remaining 14 limbs had a residual incompetent thigh GSV.
The authors concluded that despite reports to the contrary,
neovascularization occurs in a relatively small proportion of pa-
tients with REVAS.
Reflux from pelvic and abdominal veins as a cause of recurrent
varicose veins is not mentioned in this report. This is a significant
omission. It was present in 16.6% of cases in a worldwide survey of
recurrent varicose veins.2
Since the initial description by Glass,3 the prevalence of neo-
vascularization as a cause of recurrent varicose veins has been
debated. More than 50 articles both pro and con on the role of
neovascularization have been published, but it is generally agreed
that neovascularization occurs in 20% to 60% of cases following
saphenous vein surgery.
So, the question arises: Why was the rate of neovascularization
so low in this report?
As has been demonstrated in many studies, neovascularization
develops principally when the high ligation (HL) is done flush with
the femoral vein. The rate of technically inadequate flushHL in the
initial surgery is very high in this report. The rate of incorrect,
non-flush ligation in 71.0% of cases is not only surprising, but is
unacceptable. This is probably related to the fact that patients were
operated long ago when preoperative and postoperative DS were
not done systematically. However, it may also be due to the fact
that less than optimally trained surgeons under less than adequate
supervision did the surgery. Immediate, postoperative US would
have revealed the inadequate surgery earlier than the present time.
Whatever the reason, the very high incidence of inadequate surgery
explains the low rate of neovascularization.
Neovascularization is not an innocent bystander; it is a marker
for properly performed surgery in the groin for venous insuffi-
ciency and may be associated with recurrent varicose veins. Fisch-
er’s series in which one surgeon did all of the operations and did
them meticulously proves that fact.4 This 34-year clinical follow-
up study done by independent observers showed a 60% incidence
of junctional and circumjunctional reconnections (neovasculariza-
tion) after ligation of the true saphenofemoral junction and its
related tributaries. Color-coded duplex ultrasonography docu-
mented the fact that the junction ligation had been performed
correctly as shown by the absence of any patent proximal saphe-
nous remnant. The neovascularization reflux originated at the site
of the ligated saphenofemoral junction in 71% of limbs and from a
nearby circumjunctional vein in the other 29%. Of the real junc-
tional recurrences, 22 appeared as a tangled cluster, and 31 in-
volved a single-lumen varix.
In Fischer’s series, 27 recurrences in the 125 limbs studied
were sufficiently symptomatic to warrant consideration of addi-
tional treatment. This incidence in a follow-up of 34 years with
60% neovascularization proves that the neovascularization is not
just an innocent bystander. Its virtual absence in the present series
is testimony to inadequate initial surgery.
John J. Bergan, MD
University of California
San Diego School of Medicine
La Jolla, Calif
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We would like to thank Dr Bergan for his attention to our
report on a topic for which he has had an interest for a long time.
He summarizes our key findings but failed to notice that we did
report specific cross-groin/pelvic/vulval veins in seven limbs, in
four of which they were the only source of reflux. This number is
less than the 16% reported in the smaller multinational series of
199 limbs reported by Perrin.1 However, among the 188 limbs
with a GSV stump with one or more intact tributaries in our series,
many of these tributaries drained from the pelvis, the vulva, or the
abdominal wall. We believe it can be difficult to reliably determine
the source of all tributaries to the GSV stump and, therefore, did
not attempt to subcategorize this group further.
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